Latest Content

Ramy Sedhom, MD, of Penn Medicine Princeton Health discusses blending palliative care with psycho-oncology to treat patient distress in oncology care.

FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.

At WCLC 2026, Kaitlyn Gregory details key oncology nursing insights into exercise, caregiver stress, screening models, and APP-led supportive care.

For Gynecologic Cancer Awareness Month, Dr. Eleonora Teplinsky outlines emerging treatment toxicities, patient advocacy, and health equity.

FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.

Gigi Jameel, APRN, discusses supportive care interventions, ADT toxicity management, and team collaboration in prostate cancer care.

Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.

Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.

KEYNOTE-564 data show adjuvant pembrolizumab maintains DFS and OS benefits in ccRCC. Review key nursing takeaways and safety outcomes.

NCCN survey data show 100% of cancer centers face drug shortages, with ifosfamide and carboplatin critical.

Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.

The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.

FDA approves cabozantinib capsules for RCC, HCC, and epNET. Review key dosing conversions and safety guidelines for oncology nursing practice.